ATGC awarded NIH Phase I STTR grant to develop novel egg bioreactor technology
Gene edited chicken egg can be used for the safe and cost-effective therapeutic protein production. Past methods for constructing such ... Read More
ATGC awarded NIH Phase II STTR grant to continue developing miCas9 technology
Homologous recombination is the major biological mechanism underlying the gene correction and genetic modification using programmable nucleases such as CRISPR/Cas9. ... Read More
University of Michigan and ATGC publish miCas9 paper
University of Michigan and ATGC published a paper titled “MiCas9 increases large size gene knock-in rates and reduces undesirable on-target ... Read More